Timed NAD+ supplementation rescues vascular circadian dysfunction and arterial stiffness by enhancing BMAL1 transcriptional activity

Hypothesis

Restoring circadian NAD+ levels at the appropriate phase amplifies SIRT1-mediated deacetylation of BMAL1, thereby recovering nitric oxide production and reducing arterial stiffness in circadian-disrupted vasculature.

Mechanistic Rationale

Circadian genes BMAL1 and PER2 directly regulate endothelial nitric oxide synthase (eNOS) and antioxidant pathways via Nrf2/Bcl-2 [1][2]. NAD+ availability oscillates with the clock and activates SIRT1, which deacetylates BMAL1 to increase its DNA‑binding affinity and transcriptional output [3]. In obesity or sleep apnea, NAD+ rhythms flatten, SIRT1 activity drops, BMAL1 becomes hyperacetylated, and eNOS transcription falls, leading to reduced NO bioavailability, increased oxidative stress, and arterial stiffening [4][5]. Exogenous NAD+ precursors (e.g., nicotinamide riboside, NR) administered when endogenous NAD+ is low can re‑establish the amplitude of the NAD+‑SIRT1‑BMAL1 axis, restoring eNOS expression and downstream vasoprotective programs.

Experimental Design

1. Model: Use vascular smooth muscle‑specific BMAL1 knockout (VSMC‑BMAL1‑KO) mice and wild‑type controls subjected to chronic sleep‑fragmentation to mimic circadian disruption.
2. Intervention: Give NR (300 mg/kg/day) via drinking water at two circadian times: ZT6 (mid‑active phase, when NAD+ is naturally low) and ZT18 (mid‑rest phase, when NAD+ is high). A vehicle group serves as control.
3. Readouts (collected after 4 weeks):
   • Plasma and tissue NAD+ levels (LC‑MS).
   • SIRT1 activity and BMAL1 acetylation status (Western blot, immunoprecipitation).
   • eNOS mRNA and protein levels, NO production (DAF‑FM fluorescence).
   • Arterial stiffness measured by pulse wave velocity.
   • Blood pressure telemetry and atherosclerotic lesion area in the aorta (Oil‑Red‑O staining).
4. Analysis: Two‑way ANOVA (genotype × treatment) with post‑hoc tests; significance set at p<0.05.

Predicted Outcomes

• NR given at ZT6 will significantly increase NAD+ and SIRT1 activity, reduce BMAL1 acetylation, and restore eNOS expression to near‑wild‑type levels in VSMC‑BMAL1‑KO mice.
• This molecular rescue will translate into higher NO bioavailability, lower oxidative stress markers (e.g., 4‑HNE), reduced pulse wave velocity, and attenuated atherosclerotic lesion formation compared with vehicle.
• NR administered at ZT18 will produce minimal additional benefit because endogenous NAD+ is already high, demonstrating the time‑dependence of the effect.

Potential Caveats

• Compensatory upregulation of other NAD+ consuming enzymes (CD38, PARPs) could blunt NR efficacy; measuring their activity will clarify this.
• The VSMC‑BMAL1‑KO model may not fully recapitulate human sleep‑apnea pathophysiology; validating findings in a hypoxia‑induced sleep‑apnea model will strengthen translational relevance.
• Over‑supplementation of NAD+ could trigger feedback inhibition of biosynthesis pathways; dosing studies will define the therapeutic window.